Replies to post #498237 on NorthWest Biotherapeutics Inc (NWBO)

[lrdpdx77]

I'm wondering if the common stock equivalent share price that these are issued at will be higher than current common stock price thereby not resulting in dilution of value. This instrument is more valuable than common and essentially would give a large player a controlling option on acquiring NWBO. I don't think NWBO sells that at a common stock equivalent price of $.65. If any big player attempted to purchase 250 million shares on the open market the price would rise substantially above $.65., which would be a rationale for paying more than current price but less than what the price would be to purchase that many shares.

[sentiment_stocks]

They offered 15 million A and 15 million B back in 2017/18.

I think about 7 million As were sold, and less than a million Bs were sold.

Lots of Cognate debt were converted to As and Bs, of which all the As went to LP when management purchased Cognate (not Charles River) and all the Bs were later given up in negotiations on the debt.

So perhaps sometime in the future, those Cs will be used more extensively, but without an 8K regarding this current raise, even if there were a demand, the company will only raise what it needs to get it through to either the next paltry raise, or until the share price is much higher.

Dilution is no one's friend, including management's.